|
| |
Nabriva Therapeutics Appoints New Supervisory Board Member
Vienna, Austria- May 7 2009- Nabriva Therapeutics, a biotechnology
company focused on developing a new class of antibiotics for the treatment of
serious infections caused by resistant pathogens, has announced the appointment
of George H. Talbot, M.D. to its Supervisory Board.
Dr. Talbot is highly respected in the field of anti-infective drug development
and has contributed to the development of many marketed and investigational
antimicrobials. He began his pharmaceutical career at Rhone-Poulenc Rorer,
assuming positions of increasing responsibility as the company evolved into
Aventis Pharmaceuticals. From June 2006 until October 2007, Dr. Talbot served as
Executive Vice President and Chief Medical Officer of Cerexa, Inc. Cerexa, which
specializes in anti-bacterial drug development, was purchased by Forest
Laboratories in January 2007.
Dr. Talbot commented, "Nabriva is one of the most promising anti-infective
companies out there, and so I am delighted to have been invited to join the
Supervisory Board. I am particularly excited by the potential of Nabriva’s
systemically administered pleuromutilins, especially now that their lead
products are in the clinic.”
Dr. David Chiswell, CEO of Nabriva Therapeutics said: “We are delighted to have
Dr. Talbot on board. We will generate key human data in 2009 for our two lead
pleuromutilin-based antibiotics BC-3205 and BC-3781, which are being developed
to treat life-threatening infectious diseases caused by multi-drug resistant (MDR)
pathogens including methicillin-resistant Staphylococcus aureus and MDR
Streptococcus pneumoniae. Dr. Talbot’s experience in anti-infective drug
development will prove invaluable as we continue the clinical development of
these molecules.”
Dr. Talbot received his Bachelor of Arts degree in Religion and Psychology from
Wesleyan University and his Doctorate in Medicine from the Yale University
School of Medicine. He completed his training in Internal Medicine and
Infectious Diseases at the University of Pennsylvania hospitals, and then
assumed successive faculty positions at the University of Pennsylvania School of
Medicine. While at the University of Pennsylvania, Dr. Talbot’s main research
interests were the epidemiology and management of nosocomial infections,
including those occurring in patients with acute leukemia, as well as clinical
trials of new antimicrobial agents. Dr. Talbot currently sits on the scientific
advisory boards of Calixa Therapeutics, Inc. and Actelion Pharmaceuticals. He is
a fellow of the Infectious Diseases Society of America (IDSA) and a founding
member of IDSA’s Antimicrobial Availability Task Force
- ends -
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new
class of antibiotics for the treatment of serious infections caused by resistant
pathogens. The Company’s two systemically available pleuromutilin antibiotics,
BC-3205 and BC-3781, are being developed for both oral and IV administration
with extensive clinical phase I data becoming available during 2009. In
addition, Nabriva Therapeutics’ topical pleuromutilin product candidate,
BC-7013, is also in clinical phase I.
Nabriva Therapeutics has a proven track record in world-class medicinal
chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva
Therapeutics is located in Vienna, Austria.
For more information on Nabriva please visit
www.nabriva.com.
Contact:
Nabriva Therapeutics AG
Dr David Chiswell
CEO
T +43 (0)1 740 93-0
OFFICE@NABRIVA.COM
College Hill Life Sciences
Dr Douglas Pretsell
Senior Account Director
T +49 (0)89 57001806
douglas.pretsell@collegehill.com
| |
|
